Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | ICMT | O60725 | 5/20 | 0.50 |
| ▸ | FNTA | P49354 | 4/20 | 0.44 |
| ▸ | FNTB | P49356 | 4/20 | 0.44 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4032129 | 0.84 | MAPT (0.72) | MAPTKMT2AMEN1TRPA1ALDH1A1 | |
| SCHEMBL8106737 | 0.84 | KMT2A (0.53) | MAPTKMT2AMEN1ALDH1A1FNTA | |
| SCHEMBL7566818 | 0.84 | KMT2A (0.53) | MAPTKMT2AMEN1ALDH1A1FNTA | |
| SCHEMBL8103041 | 0.84 | KMT2A (0.53) | MAPTKMT2AMEN1ALDH1A1FNTA | |
| SCHEMBL7589850 | 0.84 | KMT2A (0.53) | MAPTKMT2AMEN1ALDH1A1FNTA | |
| SCHEMBL14672102 | 0.82 | MAPT (0.69) | MAPTKMT2AMEN1TRPA1ALDH1A1 | |
| SCHEMBL14672120 | 0.82 | MAPT (0.69) | MAPTKMT2AMEN1TRPA1ALDH1A1 | |
| SCHEMBL14672126 | 0.81 | KMT2A (0.67) | MAPTKMT2AMEN1TRPA1ALDH1A1 | |
| SCHEMBL14660863 | 0.81 | KMT2A (0.67) | MAPTKMT2AMEN1TRPA1ALDH1A1 | |
| SCHEMBL9323493 | 0.79 | ALOX15 (0.49) | MAPTKMT2AMEN1TRPA1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090155186-A1 | Compositions and methods for treating inflammatory conditions | SIGNUM BIOSCENCES, INC. (NJ) | 2009-06-18 | — | — | US | claimed |
| US-5202456-A | Anticarcinogenic agents; methylating transferase inhibitors; farnesyl or geranyl sulfur-, oxygen or selenium-containing derivatives | THE PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 1993-04-13 | — | — | US | claimed |
| US-20090155186-A1 | Compositions and methods for treating inflammatory conditions | SIGNUM BIOSCENCES, INC. (NJ) | 2009-06-18 | — | — | US | disclosed |
| EP-1899480-A4 | COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY CONDITIONS | SIGNUM BIOSCIENCES INC (US) | 2009-04-22 | — | — | EP | disclosed |
| EP-1899480-A1 | COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY CONDITIONS | SIGNUM BIOSCIENCES, INC. (US) | 2008-03-19 | — | — | EP | disclosed |
| WO-2006135894-A1 | COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY CONDITIONS | SIGNUM BIOSCIENCES, INC. (US) | 2006-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090155186-A1 | Compositions and methods for treating inflammatory conditions | TNF, TRAF6, RELA | MAPT 3196/4885KMT2A 3832/4885MEN1 4772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.